Home PI3K/Akt/mTOR AMPK activator - OXPHOS inhibitor - Apoptosis related activator Lixumistat (IM156) For research use only.

Lixumistat (IM156)

Synonyms: HL156A

Lixumistat (IM156), is a potent activator of AMPK that increases AMPK phosphorylation. IM156 blocks oxidative phosphorylation (OXPHOS) through the inhibition of complex I and increases apoptosis. IM156 ameliorates various types of fibrosis and inhibits tumors.

Lixumistat (IM156) Chemical Structure

Lixumistat (IM156) Chemical Structure

CAS No. 1422365-93-2

Purity & Quality Control

Batch: S960401 DMSO]63 mg/mL]false]Ethanol]20 mg/mL]false]Water]Insoluble]false Purity: 99.93%
99.93

Lixumistat (IM156) Related Products

Signaling Pathway

AMPK Signaling Pathways

AMPK Signaling Pathway

Biological Activity

Description Lixumistat (IM156), is a potent activator of AMPK that increases AMPK phosphorylation. IM156 blocks oxidative phosphorylation (OXPHOS) through the inhibition of complex I and increases apoptosis. IM156 ameliorates various types of fibrosis and inhibits tumors.
Targets
AMPK [1] OXPHOS [2]
In vitro
In vitro

IM156 (HL156A) treatment of RPMCs inhibits HG-induced myofibroblast transdifferentiation and markers of epithelial-mesenchymal transition (EMT). Moreover, IM156 (HL156A) ameliorates HG-induced transforming growth factor-β1, Smad3, Snail, and fibronectin expression in the RPMCs via AMPK upregulation.[3] IM156 treatment decreases complex I-dependent NADH oxidation in a significant, dose-dependent manner.[2]
Cell Research Cell lines Rat peritoneal mesothelial cells (RPMCs)
Concentrations 10 μM, 30 μM, 50 μM
Incubation Time 24 h
Method

RPMCs are seeded at a density of 1 × 105 cells/well on a six-well plate. RPMCs are grown to 70% confluence and serum-starved under NG conditions for 24 h. The specific AMPKα1 small interfering (si)RNA, AMPKα2 siRNA, or control siRNA are transfected into the cells using a siRNA transfection reagent according to the manufacturer’s procedure. AMPKα1 siRNA, AMPKα2 siRNA, or control siRNA are incubated at final concentration of 20 μM using siRNA dilution buffer for 30 min at RT. The cells are washed twice with 2 ml of siRNA transfection medium, and 0.8 ml siRNA transfection medium and 200 μl siRNA transfection reagent complex are added to the well, covering the entire layer. The contents of the plate are gently mixed by swirling to ensure that the entire cell layer is immersed in the solution. Then, the cells are incubated for 5 h at 37°C in a 5% CO2 incubator. After that, 1 ml of normal growth medium is added. Next, the cells are incubated for an additional 24 h. Then, the media are replaced with fresh completed media and treated with NG or HG in the presence or absence of IM156 (HL156A) for 24 h.
In Vivo
In vivo

In vivo treatment of IM156 exacerbated the memory differentiation of virus-specific CD8+ T cells results in an increase in short-lived effector cells but decrease in memory precursor effector cells. Thus, IM156 treatment impaires the function of virus-specific memory CD8+ T cells, indicating that excessive AMPK activation weakens memory T cell differentiation, thereby suppressing recall immune responses.[1]
Animal Research Animal Models 5 to 6-wk-old female C57BL/6 mice
Dosages 5 mg/kg
Administration IP

Chemical Information & Solubility

Molecular Weight 315.29 Formula

C13H16F3N5O
CAS No. 1422365-93-2 SDF --
Smiles FC(F)(F)OC1=CC=C(NC(=N)NC(=N)N2CCCC2)C=C1
Storage (From the date of receipt) 3 years -20°C powder

In vitro
Batch:

DMSO : 63 mg/mL ( (199.81 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 20 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Lixumistat (IM156) | Lixumistat (IM156) supplier | purchase Lixumistat (IM156) | Lixumistat (IM156) cost | Lixumistat (IM156) manufacturer | order Lixumistat (IM156) | Lixumistat (IM156) distributor